Smad2/3 Signaling Mediates the Atrophic Response in Vocal Fold Myoblasts In Vitro
The Laryngoscope · 2026
DOI: 10.1002/lary.32474 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Masayoshi Yoshimatsu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Smad3 Protein, Smad2 Protein, Myoblasts, Vocal Cords. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, National Institutes of Health/National Institute on Deafness and Other Communication Disorders, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Background/Objectives Vocal fold (VF) muscle atrophy, often associated with neuromuscular disorders and aging, can lead to voice‐related disability. Myostatin is well‐known to mediate skeletal muscle atrophy via Smad2/3 signaling, whereas TGF‐β1, a potent inducer of Smad2/3 signaling, is upregulated following VF injury. However, the impact of Smad2/3 signaling on laryngeal muscles remains unclear. This study provides foundational insight regarding Smad2/3‐dependent atrophic responses of VF skeletal muscle cells, to ultimately develop novel therapeutic strategies for VF muscle atrophy. Study Design In vitro.
Methods
Myoblasts isolated from the rat thyroarytenoid muscle were differentiated into myotubes in myogenic differentiation medium ±500 ng/mL myostatin or 10 ng/mL TGF‐β1, in the presence or absence of an ALK4/5 inhibitor or siRNA targeting Smad2 and Smad3. Myotube formation and activation of Smad2/3 (nuclear localization of Smad2/3) were assessed via immunofluorescence. Transcription related to myotube differentiation and Smad2/3 signaling was quantified by qRT‐PCR.
Results
Both myostatin and TGF‐β1 suppressed myogenic differentiation, increased Smad2/3 nuclear intensity, downregulated Myh2 , and upregulated downstream targets of Smad2/3 ( Ccn2 and Serpine1 ) and Fbox32 , an atrophy‐related gene. These effects were more pronounced with TGF‐β1 than with myostatin and were reversed by inhibition of ALK4/5. Furthermore, Smad2/3 knockdown via siRNA promoted myogenic differentiation, further supporting the role of Smad2/3 signaling in the atrophic response in VF myoblasts.
Conclusions
Smad2/3 signaling mediates differentiation of VF myoblasts and TGF‐β1, a potent mediator of fibrosis, elicited a more pronounced atrophic response than myostatin. Smad2/3 may be an attractive therapeutic target for VF muscle atrophy. Level of Evidence NA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otolaryngology-Head and Neck Surgery, NYU Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Masayoshi Yoshimatsu, Ryosuke Nakamura, Gary J Gartling
Förderung
- NIDCD NIH HHS
- National Institutes of Health/National Institute on Deafness and Other Communication Disorders
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Yoshimatsu, M., Nakamura, R., Bing, R., Gartling, G. J., & Branski, R. C. (2026). Smad2/3 Signaling Mediates the Atrophic Response in Vocal Fold Myoblasts In Vitro. The Laryngoscope. https://doi.org/10.1002/lary.32474
Vancouver
Yoshimatsu M, Nakamura R, Bing R, Gartling GJ, Branski RC. Smad2/3 Signaling Mediates the Atrophic Response in Vocal Fold Myoblasts In Vitro. The Laryngoscope. 2026. doi:10.1002/lary.32474
BibTeX
@article{Yoshimatsu2026,
author = {Yoshimatsu, Masayoshi and Nakamura, Ryosuke and Bing, Renjie and Gartling, Gary J and Branski, Ryan C},
title = {Smad2/3 Signaling Mediates the Atrophic Response in Vocal Fold Myoblasts In Vitro},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.32474}
}
EUVIMED